3min chapter

Biotech 2050 Podcast cover image

New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio

Biotech 2050 Podcast

CHAPTER

The Pros and Cons of a Single Asset Approach to Development

Cameron: We have been addicted to platforms for the last, let's say at least five years during this kind of last cycle. And there are some companies that really need to be a platform and give the justification for investing hundreds of millions of dollars pre-clinically on a single IP platform like Moderna or CRISPR. So my fascination is how do you create a company around those single hypothesis assets that represent the majority or at least the plurality of all drugs to be developed? He says Cambrian has an asset centric model where it starts early with pharma partnering conversations and looks for a liquidity event later in life. Cameron: If you want to be enduring R&

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode